Pharmacogenetic tests for antipsychotic medications: Clinical implications and considerations

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Optimizing antipsychotic pharmacotherapy is often challenging due to significant variability in effectiveness and tolerability. Genetic factors influencing pharmacokinetics and pharmacodynamics may contribute to some of this variability. Research studies have characterized these pharmacogenetic relationships, and some genetic markers are now available as clinical tests. These advances in pharmacogenetics research and test availability have great potential to improve clinical outcomes and quality of life in psychiatric patients. For clinicians considering using pharmacogenetics, it is important to understand the clinical implications and also the limitations of markers included in currently available tests. This review focuses on pharmacokinetic and pharmacodynamic gene variants that are currently available in commercial genetic testing panels. Associations of these variants with clinical efficacy and adverse effects, as well as other clinical implications, in antipsychotic pharmacotherapy are discussed.

Original languageEnglish (US)
Pages (from-to)323-337
Number of pages15
JournalDialogues in Clinical Neuroscience
Issue number3
StatePublished - Jan 1 2016


  • Antipsychotics
  • Pharmacodynamics
  • Pharmacogenetics
  • Pharmacokinetics
  • Polymorphism
  • Psychosis


Dive into the research topics of 'Pharmacogenetic tests for antipsychotic medications: Clinical implications and considerations'. Together they form a unique fingerprint.

Cite this